---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-031597"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:53:08.088460+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Pharmaceuticals raises ~$250M via equity offering of 7.8M shares through Jefferies

## Summary
- Entered Open Market Sale Agreement with Jefferies LLC to sell up to 7,807,620 shares of common stock.
- Estimated gross proceeds of ~$250 million after discounts, commissions, and expenses.
- Offering closed on December 2, 2022; shares issued under shelf registration statement on Form S-3.
- Company agreed to indemnify Jefferies against certain liabilities under the Securities Act.

## SEC filing metadata
- accession: 0001628280-22-031597
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/0001628280-22-031597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/arwr-20221202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-031597
- JSON: https://secwatch.observer/filing/0001628280-22-031597.json
- Plain text: https://secwatch.observer/filing/0001628280-22-031597.txt

## Key facts
- Material Agreements
  ARROWHEAD PHARMACEUTICALS, INC. entered into Open Market Sale Agreement with Jefferies LLC valued at approximately $250 million (effective 2022-12-02).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: approximately $250 million
  - Effective: 2022-12-02
  source text: On December 2, 2022, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an open market sale agreement (the “Open Market Sale Agreement”) with Jefferies LLC (the "Agent"), pursuant to which the Company agreed to issue and sell up to 7,807,620 shares of common stock (the “Shares”), par value $0.001 per share (the “Common Stock”). The Company estimates that gross proceeds from the offering will be approximately $250 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/0001628280-22-031597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.